Urologix Performance
| ULGXDelisted Stock | USD 0.0001 0.00 0.00% |
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Urologix are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Urologix has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong technical and fundamental indicators, Urologix is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
| Total Cashflows From Investing Activities | -42 K |
Urologix |
Urologix Relative Risk vs. Return Landscape
If you would invest 0.01 in Urologix on September 4, 2024 and sell it today you would earn a total of 0.00 from holding Urologix or generate 0.0% return on investment over 90 days. Urologix is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Urologix, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Urologix Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Urologix's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Urologix, and traders can use it to determine the average amount a Urologix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ULGX |
Based on monthly moving average Urologix is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Urologix by adding Urologix to a well-diversified portfolio.
Urologix Fundamentals Growth
Urologix Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Urologix, and Urologix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Urologix Pink Sheet performance.
| Return On Asset | -0.0762 | ||||
| Profit Margin | (0.39) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 4.92 M | ||||
| Shares Outstanding | 21.82 M | ||||
| Price To Sales | 0.01 X | ||||
| Revenue | 14.01 M | ||||
| EBITDA | (373 K) | ||||
| Cash And Equivalents | 492 K | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 4.59 M | ||||
| Debt To Equity | (1.81) % | ||||
| Book Value Per Share | (0.38) X | ||||
| Cash Flow From Operations | (1.53 M) | ||||
| Earnings Per Share | (0.22) X | ||||
| Total Asset | 5.67 M | ||||
| Retained Earnings | (126.63 M) | ||||
| Current Asset | 3.68 M | ||||
| Current Liabilities | 4.29 M | ||||
About Urologix Performance
Evaluating Urologix's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Urologix has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Urologix has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia in the United States. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota. UROLOGIX operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 61 people.Things to note about Urologix performance evaluation
Checking the ongoing alerts about Urologix for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Urologix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Urologix is not yet fully synchronised with the market data | |
| Urologix has some characteristics of a very speculative penny stock | |
| Urologix has a very high chance of going through financial distress in the upcoming years | |
| Urologix currently holds 4.59 M in liabilities. Urologix has a current ratio of 0.55, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Urologix until it has trouble settling it off, either with new capital or with free cash flow. So, Urologix's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Urologix sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Urologix to invest in growth at high rates of return. When we think about Urologix's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 14.01 M. Net Loss for the year was (7.61 M) with profit before overhead, payroll, taxes, and interest of 5.9 M. | |
| Urologix currently holds about 492 K in cash with (1.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Urologix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Urologix's stock is overvalued or undervalued compared to its peers.
- Examining Urologix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Urologix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Urologix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Urologix's pink sheet. These opinions can provide insight into Urologix's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Urologix Pink Sheet
If you are still planning to invest in Urologix check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Urologix's history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |